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Abstract: A dietary prebiotic is defined as ‘a substrate that is selectively utilized by host microorganisms
conferring a health benefit’. Although this definition evolved concomitantly with the knowledge
and technological developments that accrued in the last twenty years, what qualifies as prebiotic
continues to be a matter of debate. In this statement, we report the outcome of a workshop
where academic experts working in the field of prebiotic research met with scientists from industry.
The workshop covered three main topics: (i) evolution of the prebiotic concept/definition; (ii) the gut
modeling in vitro technology PolyFermS to study prebiotic effects; and (iii) the potential novel
microbiome-modulating effects associated with vitamins. The future of prebiotic research is very
promising. Indeed, the technological developments observed in recent years provide scientists with
powerful tools to investigate the complex ecosystem of gut microbiota. Combining multiple in vitro
approaches with in vivo studies is key to understanding the mechanisms of action of prebiotics
consumption and their potential beneficial effects on the host.
Keywords: gut microbiota; healthy gut; prebiotics and health benefits
1. Introduction
The human intestinal microbiota is composed of 1013–1014 microorganisms (mainly bacteria)
whose collective genome is defined as the ‘gut microbiome’ [1,2]. It is involved in several biological
processes such as nutrient utilization and energy storage [3,4], resistance against infections [5],
maturation and modulation of the immune system functions [6], and support of the neuroendocrine
functions [7] and, thus, is critical to overall health status of the host [8–12].
The microbiota–host interaction starts at birth and remains relatively stable during adulthood
while its stability decreases in the elderly [2,13] when chronic and acute perturbations frequently
appear which have been described by some as dysbiosis [9,14]. The latter occurs also in the context of
prevalent disorders such as obesity, diabetes, and metabolic inflammation [15] although it is not clear
at the present time if this is association or causation.
The concept that gut microbiota could be modulated to improve human health was proposed as
early as the beginning of the twentieth century when Elie Metchnikoff reported that Bulgarian peasants
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lived longer lives because of their yogurt consumption [16]. The idea that certain dietary components
could influence the populations of specific bacterial groups in the gut and that this could impact on
host health was further developed in the 1960s by Tomotari Mitsuoka [17,18]. Mitsuoka was the first to
link composition of diet with bacterial population and activities and health, laying the foundation for
the formulation of the prebiotic concept in the mid-1990s [19]. Indeed, an increasing number of recent
studies shows an association between human gut microbiota perturbations and pathological conditions
such as inflammatory bowel disease (IBD) [20], irritable bowel syndrome (IBS) [21], obesity [22],
and inflammation [11,14,23]. If these associations prove to be causative relationships, then this
suggests that a targeted modulation of the gut microbiota may offer preventative and maybe even
novel therapeutic approaches. A proof of principle is the recent developments of transplantation of
entire fecal microbiota in the treatment of Clostridium difficile [24,25].
In addition, nutritional interventions that can contribute to the establishment or maintenance of
a healthy gut microbiota, including the consumption of ‘prebiotics’ are gathering more attention.
The pioneering concept, as introduced by Gibson and Roberfroid in the 1990s, emphasizes the
importance of diet in the modulation of the gut microbiota and its relationships to human health.
Since then, the definition has been discussed and refined several times to accommodate emerging
knowledge. Although the main features have mostly been retained, some of the criteria that need to be
fulfilled for a food ingredient to qualify as prebiotic are still a matter of debate.
Considering our increasing knowledge of the intestinal microbiota and its importance to human
health, academic experts in the field of prebiotic research met with scientists from industry to discuss
the progress of prebiotic research beyond the traditional concept and how these developments may
stimulate the field. The workshop covered a wide range of topics including (1) the history and
evolution of the prebiotic concept; (2) available in vitro models of colonic fermentation to study
prebiotic effects; and (3) compounds with microbiome-modulating properties, such as vitamins, that
may impact host health.
2. Results
2.1. Evolution of the Prebiotic Definition
Glenn Gibson and Marcel Roberfroid first defined a prebiotic as ‘A non-digestible food ingredient
that beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited
number of bacteria in the colon, and thus improves host health’ [19]. At that time, the understanding of
the microbial ecosystem in the gut was still rather limited. Enumeration of bacteria by ‘selective’ media
was the norm and DNA-based microbiology was just being introduced. Commonly, investigators
counted around four or five functional groups and the total bacterial count and, thus, in this context
the idea of selectively stimulating ‘one or a limited number of bacteria’ as described in the definition
made perfect sense.
Nowadays, there is a deeper understanding of the gut microbiome and sequencing studies
continue to reveal the extent of the diversity of the ecosystem. These techniques, however, can also
have their flaws, resulting sometimes in a rather skewed picture without providing absolute cell counts.
They can also underrepresent functionally significant bacterial groups such as bifidobacteria depending
on methodological details [26]. In contrast, fluorescent probe-based (fluorescence in-situ hybridization
(FISH) enumeration provides the ability to count cells within defined functional groups, although
the investigator has to know what to count and cannot identify unknown diversity [27]. Developing
metagenomic and metatranscriptomic techniques will contribute considerably to our understanding
of the ecosystem in the coming years [28–31]. The first will provide access to the functional gene
composition of microbial communities, while the second will allow for the identification of expressed
transcripts in the microbiome [28]. Of note, another powerful ‘omic’ technology is metabolomics,
through which it is possible to investigate the complex host–microbiota relationship via characterization
of the microbial metabolism [32,33].
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The current picture of the gut ecosystem is one of a very diverse, highly individual, yet functionally
conserved ecosystem, and likewise the prebiotic concept has continued to evolve. According to the
definition proposed in 2008 during the 6th meeting of the International Scientific Association of
Probiotics and Prebiotics (ISAPP) in Ontario (Canada), a dietary prebiotic is ‘a selectively fermented
ingredient that results in specific changes, in the composition and/or activity of the gastrointestinal
microbiota, thus, conferring benefit(s) upon host health’ [34] and Table 1. Whilst similar to the original,
this definition has some important differences. First, the reference to ‘one or a limited number’ has
gone since it is apparent that prebiotics can bring about much more widespread changes than this.
Second, the words ‘dietary’ and ‘gastrointestinal’ were inserted with the idea to extend the concept to
other complex microbial ecosystems: such as a ‘skin prebiotic’, a ‘oral prebiotic’, or a ‘vaginal prebiotic’.
In 2017, the ISAPP consensus panel proposed another definition of a prebiotic, i.e., ‘a substrate that
is selectively utilized by host microorganisms conferring a health benefit’ [35]. The term substrate
aligns with the word ‘utilized’ and implies ‘for growth through nourishment’, excluding viable
microorganisms and antimicrobial agents as prebiotics [35]. The definition is more straightforward to
avoid unnecessary technical jargon and, like the 2008 definition, clarifies that the targets extend beyond
stimulation of bifidobacteria and lactobacilli while recognizing the health benefits that can derive from
other beneficial taxa [35]. It also first discusses substrates that, although not defined as ‘prebiotic’,
can affect composition of the microbiota through mechanisms not involving selective utilization by
host microorganisms. Examples include minerals, vitamins, and bacteriophages.
Leaving definitions aside, the way that the concept has been interpreted by investigators has
also evolved. In the early days, a rather simplistic differentiation into beneficial versus harmful
bacteria prevailed, and this resulted in an over-emphasis on stimulating populations of bifidobacteria.
They were one of the major cultivable groups and had known beneficial properties in the context of
probiotics. Concomitantly, bacteroides were frequently dismissed as harmful, although in reality this is
a huge and diverse group of bacteria with a range of impacts on the host, positive and negative [36–39].
With the two more recent ISAPP definitions [34,35], a more modern and nuanced understanding
of prebiotics now fortunately has emerged. While the central concept of selective stimulation of part
of the microbiota remains and is as valid today as it was in the 1990s, the understanding of what
this means in terms of microbial population and activity has developed [11]. Bacteria with potential
beneficial effects in IBD and obesity, such as the butyrate-producing Faecalibacterium prausnitzii, and the
mucinophilic Akkermansia muciniphila respectively, have been identified, and more will certainly be
identified as we increase our understanding of the ecosystem [40–44]. In fact, over recent years,
there has been a shift in focus away from a simplistic differentiation between beneficial and harmful
bacteria towards research aiming to understand ecological and functional features of the microbiota
relevant for host physiology [9,45–47].
In addition, recent advances in understanding the wide functions that short chain fatty acids
(SCFA) play in human physiology [48,49] has resulted in a focus on manipulation of metabolite profiles
in the gut rather than simply changing bacterial populations. Metabolomics, in this case, represents
an excellent tool to investigate the complex relationship between microbiota and host physiology.
Thus, knowledge in this field is rapidly extending, suggesting encouraging new opportunities to
improve human health. However, it is necessary to embrace all techniques available to investigate
the gut microbiome, in a way that none is superior to the others, while still providing complementary
information. Intelligent use of sequencing, quantitative PCR, FISH probing, and metabolomics can
provide a true systems biology-based approach to study prebiotics and their impact on host health.
With this approach, it is likely we will gain a much more sophisticated understanding of how prebiotics
work, which will further allow the concept to evolve.
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Table 1. Main prebiotic definitions evolved from 1995 until 2017.
Year Prebiotic Definition Reference
1995 A prebiotic is a nondigestible food ingredient that beneficially affects the host by
selectively stimulating the growth and/or activity of one or a limited number of
bacteria in the colon, and thus improves host health.
[19]
2003 Prebiotics are nondigestible substances that provide a beneficial physiological
effect on the host by selectively stimulating the favorable growth or activity of a
limited number of indigenous bacteria.
[50]
2004 A prebiotic is a selectively fermented ingredient that allows specific changes, both
in the composition and/or activity in the gastrointestinal microflora that confers
benefits upon host wellbeing and health.
[51]
2010 A prebiotic is a selectively fermented ingredient that results in specific changes in
the composition and/or activity of the gastrointestinal microbiota, thus conferring
benefit(s) upon host health.
[34]
2017 A prebiotic is a substrate that is selectively utilized by host microorganisms
conferring health benefit.
[35]
2.2. In Vitro Models of Colonic Fermentation
As part of an integrated approach to comprehensively study the functions of prebiotics on
the gut microbiota, gut models, before moving, are particularly suited to in vivo animal testing or
clinical studies in humans. In vitro gut models allow for study of the mechanistic effects of dietary,
microbial, drug, and physiological factors on gut microbiota in a highly controlled environment and at
levels that cannot be reached by an in vivo setup, and independent of the host. Therefore, in recent
years, these models have evolved rapidly overcoming the issues associated with ethical concerns and
providing with cost-effective tools for animal and human research.
A range of systems has been developed over the past decades to model fermentation of the colon
(see Figure 1), which harbors the highest density of microbes. This ranges from simple anaerobic batch
culture systems in flasks to sophisticated multi-stage continuous flow models [52,53]. It should be
emphasized that all models are different with respect to conditions and output. Therefore, the selection
of the most suitable model should be done carefully, considering their features and limits in relation
with the scientific question addressed. In particular, most models do not reproduce the sessile state
bacterial populations in the colon and do not reach the high bacterial density and microbial competition
of the gut [52]. A recent approach to solve these limitations has been developed as part of the PolyFermS
system including a process of immobilization of fecal microbiota in gel beads mimicking cell density
and competition of in vivo gut microbiota [54–56] (Figure 1). PolyFermS gut models can be expanded
to various configurations including infant, elderly, or obese donors, allowing for a comparison of a
control with different treatment effects with the same microbiota, ideal for investigating mechanisms
of action and bacterial metabolite profiles of multiple prebiotics. For example, recent experiments
confirmed that galacto-oligosaccharides (GOS), xylo-oligosaccharides (XOS), and beta-glucans are well
metabolized by a healthy adult microbiota with marked shifts in the overall metabolism, and increased
beneficial SCFA, such as butyrate and propionate. Although the use of different donors in these
experiments do not allow linking these beneficial effects to specific phylogenetic group responses,
donor-specific responses were obtained for three different microbiota representing two different
enterotypes. These findings illustrate the sensitivity and value of data obtainable from in vitro gut
models and emphasize the importance of considering that prebiotics may stimulate different bacterial
groups and metabolic pathways according to the subject microbiota profile.
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as supplements for prevention of human diseases, using such microorganisms that otherwise would
not survive the normal (i.e., oxygenated) atmosphere.
Beside vitamin B2, other non-carbohydrate compounds can modulate the gut microbiota
either through ‘selective utilization’ or other mechanisms and exert beneficial effects on the host.
The polyphenols contained in red wine, for example, were demonstrated to modulate the growth of
selected gut microbiota (increased growth of Bacteroides and Bifidobacterium genera) in humans [65].
The changes in gut microbiota following red wine consumption were associated with a reduction in
triglycerides and cholesterol, linking polyphenol intake to cardiovascular benefits for the host [65]
and confirmed by a reduction in the concentration of the C-reactive protein inflammatory marker.
A microbiome-modulating effect may also exist with minerals such as calcium [66] and iron [67,68],
and a combination of prebiotics and micronutrients [56,69]. Mice fed a high fat diet supplemented
with calcium showed lower plasma levels of the endotoxin LPS and a leaner phenotype, and this
was associated with the growth of Bacteroides and Bifidobacterium [66]. Finally, very recent studies
also show that supplementation with omega-3 polyunsaturated fatty acids (PUFA) may modify the
human gut microbiota [70,71]. Specifically, Menni and collaborators showed that, in a population
consisting of middle-aged and elderly women, circulating levels of omega-3 fatty acids are associated
with higher microbiome diversity and with a higher abundance of bacteria belonging to the family of
the short chain fatty acid-producer Lachnospiraceae [70]. Similarly, Watson and collaborators observed a
reversible increased abundance of several genera, including Bifidobacterium, Roseburia, and Lactobacillus
following omega-3 PUFA supplementation [71].
Taken all together, these data suggest that several non-carbohydrate compounds modulate the
gut microbiota, but whether all of them qualify as prebiotics is still under debate.
3. Discussion and Conclusions
Although the prebiotic definition has evolved together with the technological developments that
have characterized the last twenty years of microbiology research, what exactly qualifies as a prebiotic
continues to be a matter of debate. According to the most recent ISAPP definition [35], a prebiotic is
‘a substrate that is selectively utilized by host microorganisms conferring a health benefit’. While the
central concept of selective stimulation of part of the microbiota remains valid, the understanding
of what this means in terms of microbial population and activity has developed. Bifidobacteria and
lactobacilli do not represent the only functionally important members of gut microbiota, and metabolic
cross-feeding phenomena enhance the complexity of the gut bacterial ecosystems. The true challenge
is, thus, to relate a prebiotic to specific ecosystem shifts and/or metabolite production and finally to
the health benefits for the host.
Sophisticated in vitro models mimicking colonic fermentation to study the effects of prebiotics on
indicator species and overall composition, as well as metabolic products, have recently been developed.
However, they also exhibit limitations. For example, they only simulate the capacity of the microbiome
to ferment/utilize a certain prebiotic but do not indicate the functional implications associated with
those changes. While butyrate enhancement can be assessed in vitro, this does not always predict the
true interaction of the gut microbiota with the host cells or host-derived soluble factors [72]. For that,
additional data is needed that should be generated by integrating data from in vitro and in vivo
systems with human studies. An addition to these systems is represented by the intestinal organoids:
three-dimensional in vitro tissue models that retain many of the physiologically relevant features of
the in vivo intestinal tissue [73,74]. One important feature of these organoids is that they are robust
models in the presence of bacterial and viral challenges allowing for true co-culture experiments in
which epithelia and microbes can be maintained for extended periods of time in the same culture
dish [73]. Therefore, they represent a modular and highly adaptable model system for evaluating the
molecular basis of the host–microbe interface [73].
Scientists will continue to evolve the concept of prebiotics based on the increasing understanding
of the effects of various nutritional compounds on microbiota composition and metabolite production.
Nutrients 2017, 9, 1376 7 of 11
This includes the most recent findings of non-carbohydrate compounds such as polyphenols, minerals,
nutritional lipids, and vitamins, which so far have not been considered for their potential effects on gut
microbiota. This is not surprising considering that, under physiological conditions, at least in the case
of vitamins and lipids, most of them are absorbed in the upper small intestine but do not reach distal
parts of the GI tract. Nevertheless, whether their effects on host physiology are mediated, at least in
part, via modulating the gut microbiome is unknown and warrants further investigation.
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